161 related articles for article (PubMed ID: 17419358)
1. [The influence of CYP2C9 genetic polymorphism on the pharmacokinetics and pharmacodynamics of warfarin in patients with constant atrial fibrillation].
Sychev DA; Mikheeva IuA; Kropacheva ES; Ignat'ev IV; Bulytova IuM; Ramenskaia GV; Dobrovol'skiĭ AB; Panchenko EP; Kukes VG
Klin Med (Mosk); 2007; 85(1):57-60. PubMed ID: 17419358
[TBL] [Abstract][Full Text] [Related]
2. Impact of CYP2C9 genetic polymorphism on warfarin dose requirements in Pakistani population.
Siddiqi A; Khan DA; Khan FA; Naveed AK
Pak J Pharm Sci; 2010 Oct; 23(4):417-22. PubMed ID: 20884456
[TBL] [Abstract][Full Text] [Related]
3. Interindividual variability in sensitivity to warfarin--Nature or nurture?
Loebstein R; Yonath H; Peleg D; Almog S; Rotenberg M; Lubetsky A; Roitelman J; Harats D; Halkin H; Ezra D
Clin Pharmacol Ther; 2001 Aug; 70(2):159-64. PubMed ID: 11503010
[TBL] [Abstract][Full Text] [Related]
4. [Warfarin in the treatment of antiphospholipid syndrome].
Reshetniak TM; Kondrat'eva LV; Patrusheva NL; Patrushev LI
Ter Arkh; 2007; 79(5):47-54. PubMed ID: 17672075
[TBL] [Abstract][Full Text] [Related]
5. The role of CYP2C9 gene polymorphisms on anticoagulant therapy after heart valve replacement.
Yildirim H; Tamer L; Sucu N; Atik U
Med Princ Pract; 2008; 17(6):464-7. PubMed ID: 18836275
[TBL] [Abstract][Full Text] [Related]
6. Frequency of CYP2C9 polymorphisms affecting warfarin metabolism in a large anticoagulant clinic cohort.
Moridani M; Fu L; Selby R; Yun F; Sukovic T; Wong B; Cole DE
Clin Biochem; 2006 Jun; 39(6):606-12. PubMed ID: 16630605
[TBL] [Abstract][Full Text] [Related]
7. Standard warfarin dose in a patient with the CYP2C9*3/*3 genotype leads to hematuria.
Goto T; Miura M; Murata A; Terata K; Uno T; Yamamoto K; Abe Y
Clin Chim Acta; 2010 Sep; 411(17-18):1375-7. PubMed ID: 20420818
[TBL] [Abstract][Full Text] [Related]
8. CYP2C9 genotypes and dose requirements during the induction phase of oral anticoagulant therapy.
Peyvandi F; Spreafico M; Siboni SM; Moia M; Mannucci PM
Clin Pharmacol Ther; 2004 Mar; 75(3):198-203. PubMed ID: 15001971
[TBL] [Abstract][Full Text] [Related]
9. Influence of CYP2C9 polymorphisms, demographic factors and concomitant drug therapy on warfarin metabolism and maintenance dose.
Herman D; Locatelli I; Grabnar I; Peternel P; Stegnar M; Mrhar A; Breskvar K; Dolzan V
Pharmacogenomics J; 2005; 5(3):193-202. PubMed ID: 15824753
[TBL] [Abstract][Full Text] [Related]
10. A novel sequence variant in exon 7 of CYP2C9 gene (CYP2C9*24) in a patient on warfarin therapy.
Herman D; Peternel P; Stegnar M; Breskvar K; Dolzan V
Thromb Haemost; 2006 Jan; 95(1):192-4. PubMed ID: 16543980
[No Abstract] [Full Text] [Related]
11. [Cytochrome P4502C9(CYP2C9) gene polymorphism and safety of therapy with warfarin].
Mikheeva IuA; Kropacheva ES; Ignat'ev IV; Bulytova IuM; Ramenskaia GV; Sychev DA; Dobrovol'skiĭ AB; Panchenko EP
Kardiologiia; 2008; 48(3):52-7. PubMed ID: 18429757
[TBL] [Abstract][Full Text] [Related]
12. Oral anticoagulation with warfarin is significantly influenced by steroids and CYP2C9 polymorphisms in children with cancer.
Ruud E; Holmstrøm H; Bergan S; Wesenberg F
Pediatr Blood Cancer; 2008 Mar; 50(3):710-3. PubMed ID: 17226852
[TBL] [Abstract][Full Text] [Related]
13. Warfarin resistance with poor CYP2C9 activity and CYP2C9*1*2 genotype.
Dericioglu N; Babaoglu MO; Saygi S; Bozkurt A; Yasar U
Ann Pharmacother; 2004 May; 38(5):899. PubMed ID: 15039471
[No Abstract] [Full Text] [Related]
14. Association of CYP2C9 gene polymorphism with bleeding as a complication of warfarin therapy.
Samardzija M; Topić E; Stefanović M; Zibar L; Samardzija G; Balen S; Vcev A; Domanović D; Mirat J; Barbić J
Coll Antropol; 2008 Jun; 32(2):557-64. PubMed ID: 18756910
[TBL] [Abstract][Full Text] [Related]
15. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications.
Aithal GP; Day CP; Kesteven PJ; Daly AK
Lancet; 1999 Feb; 353(9154):717-9. PubMed ID: 10073515
[TBL] [Abstract][Full Text] [Related]
16. [Significance of cytochrome P450 2C9 genotype for the bleeding complications in patients treated with acenocoumarol].
Márk L; Márki-Zay J; Fodor L; Kondacs A; Paragh G; Katona A
Orv Hetil; 2005 Apr; 146(16):739-43. PubMed ID: 15889670
[TBL] [Abstract][Full Text] [Related]
17. [Clinical value of allele variants of cytochrome CYP2C9 gene for anticoagulation therapy with warfarin].
Sirotkina OV; Ulitina AS; Taraskina AE; Kadinskaia MI; Vavilova TV; Pchelina SN; Shvarts EI
Kardiologiia; 2005; 45(4):61-3. PubMed ID: 15940194
[TBL] [Abstract][Full Text] [Related]
18. Genetic modulation of oral anticoagulation with warfarin.
Margaglione M; Colaizzo D; D'Andrea G; Brancaccio V; Ciampa A; Grandone E; Di Minno G
Thromb Haemost; 2000 Nov; 84(5):775-8. PubMed ID: 11127854
[TBL] [Abstract][Full Text] [Related]
19. Several-fold increase in risk of overanticoagulation by CYP2C9 mutations.
Lindh JD; Lundgren S; Holm L; Alfredsson L; Rane A
Clin Pharmacol Ther; 2005 Nov; 78(5):540-50. PubMed ID: 16321620
[TBL] [Abstract][Full Text] [Related]
20. Warfarin sensitivity related to CYP2C9, CYP3A5, ABCB1 (MDR1) and other factors.
Wadelius M; Sörlin K; Wallerman O; Karlsson J; Yue QY; Magnusson PK; Wadelius C; Melhus H
Pharmacogenomics J; 2004; 4(1):40-8. PubMed ID: 14676821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
